Greenwich LifeSciences, Inc. Logo

Greenwich LifeSciences, Inc.

Developing an immunotherapy vaccine to prevent recurrence in HER2-positive breast cancer patients.

GLSI | NDAQ

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
3992 BLUEBONNET DR, BUILDING 14, 77477 STAFFORD
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company pioneering the development of GLSI-100 (also known as GP2), an immunotherapy to prevent the recurrence of breast cancer. The company's lead candidate is a peptide-based vaccine designed to activate the immune system to target HER2-positive cancer cells. GLSI-100 is aimed at patients who have undergone surgery and completed standard-of-care treatments. Following a successful Phase IIb trial that showed a significant reduction in recurrence rates and a well-tolerated safety profile, the therapy is now advancing through a global Phase III clinical trial, Flamingo-01. The treatment has been granted Fast Track Designation by the U.S. FDA, highlighting its potential to address a critical unmet need in oncology.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Greenwich LifeSciences, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Greenwich LifeSciences, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Greenwich LifeSciences, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
AGIOS PHARMACEUTICALS, INC. Logo
Pioneering cellular metabolism therapies for rare, genetically defined diseases like anemias.
United States of America AGIO
AIM ImmunoTech Inc. Logo
Develops immuno-therapeutics for cancers, immune disorders, and viral diseases.
United States of America AIM
AKANDA CORP. Logo
Cultivates and distributes pharma-quality medical cannabis for patients in legal markets worldwide.
United States of America AKAN
Akari Therapeutics Plc Logo
A clinical-stage oncology company developing next-gen ADCs for targeted cancer therapy.
United States of America AKTX
Akebia Therapeutics, Inc. Logo
Developing and commercializing novel, FDA-approved therapeutics for kidney disease.
United States of America AKBA
Akero Therapeutics, Inc. Logo
A clinical-stage biotech developing therapies for serious metabolic diseases like MASH.
United States of America AKRO
Alaunos Therapeutics, Inc. Logo
Developing TCR-T cell therapies to treat solid tumors by targeting specific cancer mutations.
United States of America TCRT
Aldeyra Therapeutics, Inc. Logo
Biotech developing therapies for ocular and systemic immune-mediated inflammation.
United States of America ALDX
Alector, Inc. Logo
Pioneers immuno-neurology therapies for neurodegenerative diseases like Alzheimer's.
United States of America ALEC
Aligos Therapeutics, Inc. Logo
Clinical-stage biopharma developing novel oral therapies for liver and viral diseases.
United States of America ALGS

Talk to a Data Expert

Have a question? We'll get back to you promptly.